These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32529824)

  • 1. Rapid Elaboration of Fragments into Leads by X-ray Crystallographic Screening of Parallel Chemical Libraries (REFiL
    Bentley MR; Ilyichova OV; Wang G; Williams ML; Sharma G; Alwan WS; Whitehouse RL; Mohanty B; Scammells PJ; Heras B; Martin JL; Totsika M; Capuano B; Doak BC; Scanlon MJ
    J Med Chem; 2020 Jul; 63(13):6863-6875. PubMed ID: 32529824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystallographic analysis of TPP riboswitch binding by small-molecule ligands discovered through fragment-based drug discovery approaches.
    Warner KD; Ferré-D'Amaré AR
    Methods Enzymol; 2014; 549():221-33. PubMed ID: 25432751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F2X-Universal and F2X-Entry: Structurally Diverse Compound Libraries for Crystallographic Fragment Screening.
    Wollenhaupt J; Metz A; Barthel T; Lima GMA; Heine A; Mueller U; Klebe G; Weiss MS
    Structure; 2020 Jun; 28(6):694-706.e5. PubMed ID: 32413289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein X-ray Crystallography and Drug Discovery.
    Maveyraud L; Mourey L
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallographic fragment screening.
    Badger J
    Methods Mol Biol; 2012; 841():161-77. PubMed ID: 22222452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based discovery of focal adhesion kinase inhibitors.
    Grädler U; Bomke J; Musil D; Dresing V; Lehmann M; Hölzemann G; Greiner H; Esdar C; Krier M; Heinrich T
    Bioorg Med Chem Lett; 2013 Oct; 23(19):5401-9. PubMed ID: 23973211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragments as Novel Starting Points for tRNA-Guanine Transglycosylase Inhibitors Found by Alternative Screening Strategies.
    Hassaan E; Eriksson PO; Geschwindner S; Heine A; Klebe G
    ChemMedChem; 2020 Feb; 15(3):324-337. PubMed ID: 31808981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
    Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
    J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient exploration of chemical space by fragment-based screening.
    Hall RJ; Mortenson PN; Murray CW
    Prog Biophys Mol Biol; 2014; 116(2-3):82-91. PubMed ID: 25268064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based drug design.
    Feyfant E; Cross JB; Paris K; Tsao DH
    Methods Mol Biol; 2011; 685():241-52. PubMed ID: 20981527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting the success of fragment screening by X-ray crystallography.
    Davies DR; Begley DW; Hartley RC; Staker BL; Stewart LJ
    Methods Enzymol; 2011; 493():91-114. PubMed ID: 21371588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragments: where are we now?
    Osborne J; Panova S; Rapti M; Urushima T; Jhoti H
    Biochem Soc Trans; 2020 Feb; 48(1):271-280. PubMed ID: 31985743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Native State Mass Spectrometry, Surface Plasmon Resonance, and X-ray Crystallography Correlate Strongly as a Fragment Screening Combination.
    Woods LA; Dolezal O; Ren B; Ryan JH; Peat TS; Poulsen SA
    J Med Chem; 2016 Mar; 59(5):2192-204. PubMed ID: 26882437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of N-ethylmethylamine as a novel scaffold for inhibitors of soluble epoxide hydrolase by crystallographic fragment screening.
    Amano Y; Tanabe E; Yamaguchi T
    Bioorg Med Chem; 2015 May; 23(10):2310-7. PubMed ID: 25862210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise of fragment-based drug discovery.
    Murray CW; Rees DC
    Nat Chem; 2009 Jun; 1(3):187-92. PubMed ID: 21378847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening Ligands by X-ray crystallography.
    Davies DR
    Methods Mol Biol; 2014; 1140():315-23. PubMed ID: 24590727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Throughput Crystallography: Reliable and Efficient Identification of Fragment Hits.
    Schiebel J; Krimmer SG; Röwer K; Knörlein A; Wang X; Park AY; Stieler M; Ehrmann FR; Fu K; Radeva N; Krug M; Huschmann FU; Glöckner S; Weiss MS; Mueller U; Klebe G; Heine A
    Structure; 2016 Aug; 24(8):1398-1409. PubMed ID: 27452405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.